Background
Enzo Biochem held patents covering nucleic acid probes designed to hybridize with specific sequences of Neisseria gonorrhoeae (the bacterium that causes gonorrhea) for use in diagnostic tests. Gen-Probe challenged the patents, arguing that the claims were invalid because the specifications failed to adequately describe the claimed nucleic acid sequences — instead relying primarily on the deposit of biological materials with the American Type Culture Collection (ATCC) rather than explicit written disclosure of the sequences themselves.
The district court held the patents invalid for lack of written description, finding that a deposit alone could not satisfy § 112’s requirement that the specification describe the claimed invention in sufficient detail. Enzo appealed, and the Federal Circuit agreed to hear the case en banc to clarify the relationship between the written description requirement and the enablement requirement, and to address whether biological deposits could satisfy written description.
The Court’s Holding
The Federal Circuit reversed and remanded, holding that: (1) the written description requirement in § 112 is a separate and independent requirement from enablement — a specification can enable a claim without adequately describing it, and vice versa; and (2) the deposit of biological materials in a recognized public depository like the ATCC can satisfy the written description requirement, provided the deposit was made before the filing date and the material is accessible to the public upon issuance.
The court rejected the view that written description required explicit textual description of every aspect of the claimed invention. For biological materials that are inherently difficult to describe in words — such as specific nucleic acid sequences — an accessible deposit can provide what text cannot: a precise, reproducible, publicly accessible embodiment of the claimed subject matter. The deposit functions as an extension of the specification, communicating the nature of the invention as clearly as any written sequence listing.
Key Takeaways
- The written description requirement of § 112 is legally and analytically separate from the enablement requirement — they must each be independently satisfied.
- Deposit of biological materials (such as cell lines, microorganisms, or nucleic acid sequences) in a recognized public depository can satisfy the written description requirement for biotechnology inventions.
- The written description inquiry asks whether a person of ordinary skill in the art, reading the specification (including any deposits incorporated by reference), would recognize that the inventor possessed the claimed invention at the time of filing.
- Biotechnology patent prosecutors should consider making ATCC or other public deposits before filing to secure written description support for claims to biological materials that are difficult to characterize structurally in prose.
Why It Matters
Enzo Biochem v. Gen-Probe resolved a circuit split about the independence of written description and enablement, and clarified a critically important question for biotechnology patent practice: whether a deposit could substitute for explicit textual description. The ruling had lasting effects on how pharmaceutical and biotech companies prosecute patents covering nucleic acids, antibodies, cell lines, and other biological materials.
The case also set the stage for subsequent Federal Circuit and Supreme Court decisions that further refined the written description requirement for genus claims in biotechnology — a doctrine that remains actively litigated today in disputes over broad platform biology patents. For companies that rely on patent protection for novel biological sequences or materials that cannot easily be described in words, the ruling established the practical and legal framework for using deposits to anchor their claims.